Novartis drug Votubia® receives EU approval to treat refractory partial-onset seizures in patients with TSC
/
/
Novartis drug Votubia® receives EU approval to treat refractory partial-onset seizures in patients with TSC

Basel, January 31, 2017 – Novartis today announced that the European Commission has approved Votubia® (everolimus) dispersible tablets* as an adjunctive treatment for patients aged two years and older whose refractory partial-onset seizures, with or without secondary generalization, are associated with tuberous sclerosis complex (TSC). Votubia is now the first approved pharmacologic therapy in all 28 member states of the European Union (EU), plus Iceland and Norway, specifically for the treatment of refractory partial-onset seizures associated with TSC2.

READ FULL PRESS RELEASE

Start typing and press Enter to search

Shopping Cart
Skip to content